Chinese authorities have approved Novo Nordisk's Ozempic
In April, Novo Nordisk received marketing authorization in China for the drug Ozempic, which is the firm’s newest injection-based GLP-1 product.
BY MIKKEL AABENHUS HEMMINGSEN, TRANSLATED BY NIELSINE NIELSEN
More than three years after the injection-based treatment Ozempic was approved in the EU and the US, Chinese authorities have now approved the treatment, according to Novo Nordisk's interim report for the first quarter of 2021, which was published early Wednesday.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Novo Nordisk beats expectations – upgrades outlook
For subscribers
